Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) EPS (Weighted Average and Diluted) (2020 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with -$0.71 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, EPS (Weighted Average and Diluted) fell 12.7% year-over-year to -$0.71, compared with a TTM value of -$3.47 through Dec 2021, down 69.27%, and an annual FY2024 reading of -$1.27, up 32.45% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.71 for Q4 2021 at Black Diamond Therapeutics, up from -$0.97 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.41 in Q2 2020 and bottomed at -$0.97 in Q3 2021.